NASDAQ:KTOV
Delisted
Kitov Pharamceuticals Holdings Ltd. Stock News
$2.94
+0 (+0%)
At Close: Aug 17, 2022
Purple Biotech to Present at the B. Riley Oncology Investor Conference
07:41am, Monday, 18'th Jan 2021
REHOVOT, Israel, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”) (NASDAQ/TASE: PPBT), a clinical-stage company advancing first-in-class therapies to overcome tumor immune
Kitov Announces Name Change to Purple Biotech Ltd.
08:18am, Thursday, 10'th Dec 2020
New Name Reflects Company's Evolution to Advancing First-in-Class Oncology Therapies
Kitov Pharma to Participate in November Investor Conferences
07:25am, Wednesday, 11'th Nov 2020
TEL AVIV, Israel, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion an
The new cohort will explore the combination of CM24, Opdivo (“nivolumab”) and Abraxane (“albumin-bound paclitaxel; nab-paclitaxel”) in patients with pancreatic cancer The new cohort will explo
Kitov Pharma Receives Notice of Allowance for a U.S. Patent Covering its Anti-Cancer Drug Candidate, NT219
08:03am, Tuesday, 27'th Oct 2020
Patent covers NT219's combinations with multiple 2nd and 3rd generation EGFR inhibitors, including osimertinib (TAGRISSO®)
Kitov Pharma Announces ADS Ratio Change
08:55pm, Wednesday, 12'th Aug 2020
TEL AVIV, Israel, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion an
Kitov Pharma Provides Corporate Update and Reports First Half 2020 Financial Results
11:15am, Tuesday, 11'th Aug 2020
TEL AVIV, Israel, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion an
Kitov Announces Initiation of Phase 1/2 Clinical Trial of NT219 in Advanced Cancer Patients
11:30am, Thursday, 09'th Jul 2020
Company Evaluating NT219 as Monotherapy Treatment of Advanced Solid Tumors and in Combination with Cetuximab for the Treatment of Recurrent and/or Metastatic Solid Tumors and.
Kitov Pharma Receives Notice of Intention to Grant a European Patent Covering CM24, its anti-CEACAM1 Antibody
11:30am, Wednesday, 08'th Jul 2020
Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced receipt of a not
Kitov Pharma Issues CEO Shareholder Letter Providing Business Update
12:34pm, Thursday, 02'nd Jul 2020
Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, is pleased to provide the followi
Kitov Closes $35.0 Million Registered Direct Offering
08:30pm, Thursday, 25'th Jun 2020
TEL-AVIV, Israel, June 25, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion
Urban One: Anatomy Of A Stock Bubble
02:23pm, Wednesday, 24'th Jun 2020
An influx of new retail investors and a resurgence of day trading is creating price bubbles in many small-cap stocks. This is a study of one such bubble, but it
Kitov Announces $35.0 Million Registered Direct Offering
05:20pm, Tuesday, 23'rd Jun 2020
TEL-AVIV, Israel, June 23, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion
Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that the U.S. Foo
Kitov Announces U.S. Commercial Launch of Consensi™
11:30am, Wednesday, 20'th May 2020
Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced the U.S. commerci
